NCT07007533View on ClinicalTrials.gov

A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

July 4, 2025

Primary Completion Date

July 17, 2025

Study Completion Date

July 17, 2025

Conditions

Healthy Adult

Interventions

DRUG

DA-5223-R

once a day

DRUG

DA-5223

once a day

Trial Locations (1)

13520

CHA Global Clinical Trials Center, Seongnam-si

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY